NCT02755714View on ClinicalTrials.gov

Atrovent in Exercise Induced Laryngeal Obstruction (EILO)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 22, 2016

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Exercise Induced Laryngeal Obstruction (EILO)
Interventions
DRUG

Ipratropium bromide spray

The patient will - or will not - receive Ipratropium bromide spray (MDI) 20 μg given through a plastic spacer two puffs 1 hour before a continuous laryngoscopy exercise test (CLE-test)

Trial Locations (1)

5021

Haukeland University Hospital, Bergen

All Listed Sponsors
lead

Haukeland University Hospital

OTHER

NCT02755714 - Atrovent in Exercise Induced Laryngeal Obstruction (EILO) | Biotech Hunter | Biotech Hunter